A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents-Reference-Cited by-同舟云学术

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Published:2023-12-01 Issue:1 Volume:103 Page:105-116
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Bewersdorf Jan Philipp^ORCID,Shallis Rory M.,Sharon Elad,Park Silvia,Ramaswamy Rahul,Roe Caroline E.,Irish Jonathan M.,Caldwell Anne,Wei Wei,Yacoub Abdulraheem,Madanat Yazan F.,Zeidner Joshua F.,Altman Jessica K.,Odenike Olatoyosi,Yerrabothala Swaroopa,Kovacsovics Tibor,Podoltsev Nikolai A.,Halene Stephanie,Little Richard F.,Piekarz Richard,Gore Steven D.,Kim Tae Kon,Zeidan Amer M.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05552-4.pdf

Reference41 articles.

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDSSSG (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232. https://doi.org/10.1016/S1470-2045(09)70003-8

2. Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ (2018) Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 131(7):818–821. https://doi.org/10.1182/blood-2017-10-811729

3. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK et al (2017) Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35(24):2745–2753. https://doi.org/10.1200/JCO.2015.66.2510

4. Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Adès L, Quesnel B, Beach CL, Fenaux P, Vey N (2011) Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 29(24):3322–3327. https://doi.org/10.1200/jco.2011.35.8135

5. Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G (2017) Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer J 7(12):644–644. https://doi.org/10.1038/s41408-017-0018-7

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

2. Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology;Regulatory Mechanisms in Biosystems;2024-02-17